NWRD08 not checked
Newish Biotech (Wuxi) Co., Ltd.
FollowEvery change as it happens, and a Monday email
Trials
1 active
2 in total
What this is
- How it works
- How it works isn't classified yet
- How it’s given
- “NWRD08 delivered via IM injection + electroporation using TERESA device”In the company’s words, NCT07175662 on ClinicalTrials.gov
- Main trialPhase 2
- “This is a randomized, double-blind, placebo controlled Phase 2 study to determine the efficacy and safety of NWRD08 administered by intramuscular (IM) injection followed by electroporation (EP) in adult women with histologically confirmed cervical high grade squamous intraepithelial lesion (HSIL) (cervical intraepithelial neoplasia grade 2 \[CIN2\] or grade 3 \[CIN3\]) associated with human papillomavirus (HPV) 16 and/or HPV18.”In the company’s words, NCT07175662 on ClinicalTrials.gov
Other drugs for High-grade Squamous Intraepithelial Lesion (HSIL)
- EGCG and Quinine Sulfate Vaginal SuppositoryAmplexd Therapeutics, Inc. · Phase 2
- NWRD09Newish Biotech (Wuxi) Co., Ltd. · Phase 2
Coming up1
- 30 May 2027Phase 2 trial completes · ClinicalTrials.gov
Changes0
Last 90 daysNo changes yet. We started recording changes on 6 Nov 2026.
Trials2
| Trial | Phase | Completes | What it tests |
|---|---|---|---|
| Phase 2Recruiting | 30 May 2027 | Evaluation of NWRD08 for HPV-16 and/or HPV-18 Related Cervical HSIL | |
| Phase 1Completed | 19 Feb 2025 | NWRD08 DNA Plasmid for HPV-16 and/or HPV-18 Related Cervical HSIL |
A trial in both registries shows both numbers.
About
- Sources
- ClinicalTrials.gov updated 18 Nov 2026 · EU trials register (CTIS) updated 18 Nov 2026 · openFDA updated 17 Nov 2026